Literature DB >> 19386586

Neural respiratory drive in obesity.

J Steier1, C J Jolley, J Seymour, M Roughton, M I Polkey, J Moxham.   

Abstract

BACKGROUND: The load imposed on ventilation by increased body mass contributes to the respiratory symptoms caused by obesity. A study was conducted to quantify ventilatory load and respiratory drive in obesity in both the upright and supine postures.
METHODS: Resting breathing when seated and supine was studied in 30 obese subjects (mean (SD) body mass index (BMI) 42.8 (8.6) kg/m(2)) and 30 normal subjects (mean (SD) BMI 23.6 (3.7) kg/m(2)), recording the electromyogram of the diaphragm (EMGdi, transoesophageal multipair electrode), gastric and oesophageal pressures.
RESULTS: Ventilatory load and neural drive were higher in the obese group as judged by the EMGdi (21.9 (9.0) vs 8.4 (4.0)%max, p<0.001) and oesophageal pressure swings (9.6 (2.9) vs 5.3 (2.2) cm H(2)O, p<0.001). The supine posture caused an increase in oesophageal pressure swings to 16.0 (5.0) cm H(2)O in obese subjects (p<0.001) and to 6.9 (2.0) cm H(2)O in non-obese subjects (p<0.001). The EMGdi increased in the obese group to 24.7 (8.2)%max (p<0.001) but remained the same in non-obese subjects (7.0 (3.4)%max, p = NS). Obese subjects developed intrinsic positive end-expiratory pressure (PEEPi) of 5.3 (3.6) cm H(2)O when supine. Applying continuous positive airway pressure (CPAP) in a subgroup of obese subjects when supine reduced the EMGdi by 40%, inspiratory pressure swings by 25% and largely abolished PEEPi (4.1 (2.7) vs 0.8 (0.4) cm H(2)O, p = 0.009).
CONCLUSION: Obese patients have substantially increased neural drive related to BMI and develop PEEPi when supine. CPAP abolishes PEEPi and reduces neural respiratory drive in these patients. These findings highlight the adverse respiratory consequences of obesity and have implications for the clinical management of patients, particularly where the supine posture is required.

Entities:  

Mesh:

Year:  2009        PMID: 19386586     DOI: 10.1136/thx.2008.109728

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  39 in total

Review 1.  Respiratory complications of obesity.

Authors:  Swapna Mandal; Nicholas Hart
Journal:  Clin Med (Lond)       Date:  2012-02       Impact factor: 2.659

2.  Screening for sleep-disordered breathing in a bariatric population.

Authors:  Kate Reed; Martino F Pengo; Joerg Steier
Journal:  J Thorac Dis       Date:  2016-02       Impact factor: 2.895

3.  A brief history of fluid and sleep.

Authors:  Brian D Kent; Joerg Steier
Journal:  Am J Respir Crit Care Med       Date:  2015-06-01       Impact factor: 21.405

Review 4.  Neurogenic changes in the upper airway of obstructive sleep apnoea.

Authors:  Julian P Saboisky; Jane E Butler; Billy L Luu; Simon C Gandevia
Journal:  Curr Neurol Neurosci Rep       Date:  2015-04       Impact factor: 5.081

5.  [Standard pO2 for differentiation of primary and secondary hypoxemia].

Authors:  N Frost; S Rosseau
Journal:  Med Klin Intensivmed Notfmed       Date:  2014-02       Impact factor: 0.840

Review 6.  Acute cardiopulmonary failure from sleep-disordered breathing.

Authors:  Gordon E Carr; Babak Mokhlesi; Brian K Gehlbach
Journal:  Chest       Date:  2012-03       Impact factor: 9.410

7.  Central sleep apnea in obese children with sleep-disordered breathing.

Authors:  C H Chou; K T Kang; W C Weng; P L Lee; W C Hsu
Journal:  Int J Obes (Lond)       Date:  2013-09-19       Impact factor: 5.095

Review 8.  Obesity: challenges to ventilatory control during exercise--a brief review.

Authors:  Tony G Babb
Journal:  Respir Physiol Neurobiol       Date:  2013-05-21       Impact factor: 1.931

9.  Excessive daytime sleepiness in sleep disorders.

Authors:  Gemma Slater; Joerg Steier
Journal:  J Thorac Dis       Date:  2012-12       Impact factor: 2.895

Review 10.  Clinical consequences of altered chemoreflex control.

Authors:  Maria Plataki; Scott A Sands; Atul Malhotra
Journal:  Respir Physiol Neurobiol       Date:  2013-05-13       Impact factor: 1.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.